RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Surface Oncology Stock

Surface Oncology P/S 2025

Surface Oncology P/S

7.51

Ticker

SURF

ISIN

US86877M2098

WKN

A2JJ8Q

As of May 6, 2025, Surface Oncology's P/S ratio stood at 7.51, a 0% change from the 0 P/S ratio recorded in the previous year.

The Surface Oncology P/S history

Surface Oncology Aktienanalyse

What does Surface Oncology do?

Surface Oncology Inc is a biopharmaceutical company focused on researching and developing treatments for cancer patients. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. Surface Oncology is working towards developing a new generation of immunotherapies that activate both tumor and immune cells to make the fight against cancer more effective. The company utilizes its expertise in immunology to identify and develop novel approaches to cancer treatment. The company's business model is based on a combination of internal research and development activities and collaborations with industry partners. Surface Oncology has a wide range of business partners from the pharmaceutical industry and financial investors who support the development of new products and technologies. Surface Oncology has three different divisions: research and development, clinical development, and partnerships. In the research and development division, the company works on identifying new approaches to cancer treatment and developing new products and technologies. These products are then used for evaluation in clinical trials in the clinical development division. Partnerships allow Surface Oncology to benefit from the expertise and experience of its partners, enabling faster progress in the development and commercialization of new products and technologies. The company's most well-known product is the SRF231 molecule, which is in Phase I of clinical development. It is a novel immunotherapy that aims to promote the activation of T-cells to specifically target cancer cells in the body. SRF231 was originally developed by Novartis and licensed by Surface Oncology in 2016. Surface Oncology also has a pipeline of products in preclinical development. These include the SRF617 molecule, which aims to directly attack tumor cells, and the SRF388 molecule, which targets the body's immune system to the tumor antigen TARGET. In addition to its R&D and clinical development activities, Surface Oncology has a variety of partnerships with different pharmaceutical and life science companies. In 2017, the company announced a strategic collaboration with Novartis to improve the use of immunotherapies in cancer treatment. Surface Oncology aims to revolutionize the treatment of cancer patients by developing novel immunotherapies that target the diseased tissue and activate the immune system. The company has made significant progress in the development of products like SRF231, and it has a clear vision for developing a comprehensive portfolio of cancer treatments based on the immunotherapy platform. Surface Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Surface Oncology's P/S Ratio

Surface Oncology's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Surface Oncology's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Surface Oncology's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Surface Oncology’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Surface Oncology stock

What is the price-to-earnings ratio of Surface Oncology?

The price-earnings ratio of Surface Oncology is currently 7.51.

How has the price-earnings ratio of Surface Oncology changed compared to last year?

The price-to-earnings ratio of Surface Oncology has increased by 0% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Surface Oncology high compared to other companies?

Yes, the price-to-earnings ratio of Surface Oncology is high compared to other companies.

How does an increase in the price-earnings ratio of Surface Oncology affect the company?

An increase in the price-earnings ratio of Surface Oncology would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Surface Oncology affect the company?

A decrease in the price-earnings ratio of Surface Oncology would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Surface Oncology?

Some factors that influence the price-earnings ratio of Surface Oncology are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Surface Oncology pay?

Over the past 12 months, Surface Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Surface Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Surface Oncology?

The current dividend yield of Surface Oncology is .

When does Surface Oncology pay dividends?

Surface Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Surface Oncology?

Surface Oncology paid dividends every year for the past 0 years.

What is the dividend of Surface Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Surface Oncology located?

Surface Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Surface Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Surface Oncology from 5/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/6/2025.

When did Surface Oncology pay the last dividend?

The last dividend was paid out on 5/6/2025.

What was the dividend of Surface Oncology in the year 2024?

In the year 2024, Surface Oncology distributed 0 USD as dividends.

In which currency does Surface Oncology pay out the dividend?

The dividends of Surface Oncology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Surface Oncology

Our stock analysis for Surface Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Surface Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.